CELLECTISAct. Nom. News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

29.10.12	Cellectis Presents Breakthrough in Fight against Cancer at ESGCT Congress (Businesswire)
25.10.12	Cellectis extends its TAL technology intellectual property portfolio through the acquisition of two exclusive licenses from Iowa State University (Businesswire)
23.10.12	Cellectis bioresearch Inc. wins a $6.9 million contract with The National Institutes of Health on iPS cells (Businesswire)
16.10.12	The National Institutes of Health awarded a contract to Cellectis bioresearch Inc. (Businesswire)
08.10.12	Cellectis: the Award of Nobel Prize in Medicine to Professor Yamanaka Confirms the Relevance of the Group's Stem Cell Strategy (Businesswire)
04.10.12	Medicago and Cellectis Successfully Achieve First Step in Research Collaboration (Businesswire)
02.10.12	Cellectis Publishes Results Paving the Way for New Therapeutic Approaches against Cancer and Genetic Diseases (Businesswire)
24.09.12	Cellectis stem cells today announces the release of a new and improved user friendly format of stem cell derived cardiomyocytes (Businesswire)
20.09.12	Cellectis: 2012 first-half earnings (Businesswire)
10.09.12	Cellectis: A step towards a new therapy for AIDS (Businesswire)
25.06.12	Combined general meeting for Cellectis shareholders on June 22nd, 2012 (Businesswire)
21.05.12	Cellectis stem cells today proudly announces the launch of the world’s very first human iPS cell-derived hepatocyte product (Businesswire)
02.04.12	Appointment of Mathieu Simon, MD, to the Position of Senior Vice-President of Cellectis Group (Businesswire)
13.02.12	Cellectis announces the redemption of the bonds redeemable into shares subscribed by the FSI and Pierre Bastid for a total of €50 million (Businesswire)
31.01.12	Cellectis Plant Sciences Announces the Signature of a Strategic Partnership with SESVanderHave in Sugar Beet (Businesswire)
30.01.12	Changes in the Group's Scientific Division and Appointment of the CEO of Cellectis Plant Sciences (Businesswire)
16.01.12	Medicago and Cellectis Enter into Research Agreement to Improve Therapeutic Proteins Using Nuclease Technology (Businesswire)
09.01.12	Cellectis Launches a Partnership with Total for Exploratory Research into Microalgae-Based Substitutes for Oil Products (Businesswire)
03.01.12	Cellectis plant sciences and Bayer CropScience strengthen genome engineering partnership (Businesswire)
08.12.11	Cellectis bioresearch and Syngene Announce Partnership on the Development of Customized Cell Lines (Businesswire)
08.12.11	Starbucks Enters Five New Cities Across Mainland China (Businesswire)
05.12.11	Cellectis Signs a License Agreement Under Patents Covering Uses of Homologous Recombination With Global Pharmaceutical Company (Businesswire)
07.11.11	Cellectis Announces the Final Completion of the Acquisition of Cellartis and €50 Million Financing Round Reserved for the FSI and Mr. Pierre Bastid (Businesswire)
14.10.09	Cellectis Launches a Capital Increase without Preferential Subscription Rights Through a Private Placement to Qualified Investors of Approximately € 20 Million (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	77.62	1.81 %	K V
CieFinRichemont	122.35	0.99 %	K V
Lonza Grp	531.00	0.84 %	K V
Zurich Insur Gr	553.00	0.18 %	K V
Novartis	91.93	0.00 %	K V
ABB	49.54	-0.84 %	K V
Swisscom	504.00	-0.98 %	K V
Sika	228.60	-1.12 %	K V
Holcim	88.42	-1.51 %	K V
UBS Group	27.76	-2.08 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu CELLECTISAct. Nom.

Aktien Top/Flop

Meistgelesene Nachrichten